Invus manages over $10 billion of evergreen capital backed by a European family group, partnering with visionary management teams for the long term. The firm makes both majority and minority investments across venture, growth, and buyout stages, with a strong focus on transformational strategies in biotechnology, medical devices, and healthcare.
About Invus
Invus is a New York-based long-horizon investment firm with origins as the family office of the Belgian Frere family, deploying patient capital into operating companies and growth investments across consumer, healthcare, life sciences, and technology. The firm distinguishes itself from traditional VC by operating without a fund clock, often holding investments for a decade or more, and is willing to lead growth and late-stage rounds with checks ranging from $20M to $200M-plus. Healthcare exposure is meaningful and includes biotech, life sciences platforms, and selectively healthcare services and digital health, with the firm comfortable leading rounds and taking board seats. AI focus is welcome where it sits inside a durable healthcare business with clear commercial fundamentals. Founders best suited are growth and late-stage CEOs with $20M-plus revenue or compelling biotech platforms, who would benefit from a long-term, deep-pocketed lead investor who can fund multiple rounds and is patient about exit timing. Founders who do not fit include seed and Series A teams, consumer wellness, and capital-light services businesses that do not need Invus-scale checks. Geographic preference is global with a US and European focus. The entry path is warm introduction through a portfolio CEO, a senior healthcare banker, or a top-tier financial co-investor. LinkedIn outreach is unlikely to convert without a strong reference path. Expect deliberate, evidence-driven diligence and a partner that values durability and pricing discipline over fast capital deployment.
Founder reviews
Other portfolio companies
Companies in Invus's portfolio not currently in our directory.
- Absci · 2026
- Osanni Bio · 2026
- Lycia Therapeutics · 2024
- Contraline · 2026
- Ray Therapeutics · 2026
- TRIANA Biomedicines · 2025
- Triveni Bio · 2023
- Ring Therapeutics · 2025
- PrognomiQ · 2020
- Presidio Medical · 2020
- Pretzel Therapeutics · 2022
Team
Pitch / review this investor
Have you raised from Invus? Founders only — share your honest experience (anonymous OK, moderated before publishing).